It is the first vaccine of its kind to reach a late-stage, mass-scale human trial, according to China National Biotec Group.
The results showed a good safety record and no severe adverse reactions were found in clinical trials, and vaccine receivers inoculated with two injections in different procedures and doses have all produced high titers of antibodies.
The UAE and China collaboration is not the only vaccine at the Phase 3 stage. The results of the tests, which were conducted on people who were injected with the vaccine, and who received two doses of it during a period of 28 days, indicated a positive antibody transformation rate of 100%.
While most candidates are in Phase 1 or simultaneous Phase 1 and 2 of clinical trials, those from Moderna Therapeutics in the U.S. and the University of Oxford in the United Kingdom are leading the race.
If the vaccine is confirmed to be safe and effective throughout the entire clinical trial process, it is regarded as successful and then enters into a large-scale manufacturing phase.
The clinical research of vaccines is typically divided into three phases - phase I, phase II, and phase III.
Around 90 per cent of the world's population is still susceptible to the coronavirus, making the search for a vaccine vital, the World Health Organization's chief scientist has said. Common recombinant vaccines include those against hepatitis B, influenza, whooping cough and human papillomavirus or HPV. Therefore, scientists have chosen to focus on the spike protein as one of the major targets for vaccines and therapeutics.
It also said the viral load in the test animals decreased noticeably, reducing the virus' damage to lung tissues.
Through this agreement, Stevanato Group, which produces 10 billion units a year of drug delivery systems, sterile and bulk glass containers, plastic diagnostic and medical components, becomes a key supplier to CEPI's COVID-19 vaccine programs.
From the costing, production, safety and efficacy, there are a lot of factors into play which decide how helpful a vaccine under development really is.
AstraZeneca, Oxford's partner, has collaborated with the Serum Institute of India, the world's largest vaccine manufacturer by doses, to manufacture/supply a billion doses of its COVID-19 vaccine to India and other low-and-middle-income countries.